Noboru Yamamoto

Also affiliated with National Cancer Center Hospital East, Tokyo National Hospital

Biochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non–Small-Cell Lung Cancer: A Retrospective Analysis”.

Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non–Small-Cell Lung Cancer: A Retrospective Analysis

Clinical Lung Cancer(2017)10.1016/j.cllc.2016.11.015

N/A

0.888DataRank · unranked

18 citations

Yutaka Fujiwara, Kota Itahashi, Shinsuke Kitahara, Yasushi Goto, Hidehito Horinouchi +6 more

473P A phase I study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients with advanced solid tumors including colorectal cancer (CRC)

Annals of Oncology(2021)10.1016/j.annonc.2021.08.994

N/A

0DataRank · unranked

1 citations

Satoru Iwasa, Kohei Shitara, Takafumi Koyama, Yujiro Ueda, Satoshi Nagao +7 more